Medpace Holdings (FRA:01P) E10: €6.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:01P Medpace Holdings Inc FRA:01P
95 GF Score
Price €530.40
GF Value €463.14
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings E10?

Medpace Holdings FRA:01P +0.49% 95 E10 is €6.48 as of Jun. 2026. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Medpace Holdings's adjusted earnings per share data for the three months ended in Jun. 2026 was €3.689. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €6.48 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Medpace Holdings's average E10 Growth Rate was 35.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-25), Medpace Holdings's current stock price is €530.40. Medpace Holdings's E10 for the quarter that ended in Jun. 2026 was €6.48. Medpace Holdings's Shiller PE Ratio of today is 81.85.

During the past 13 years, the highest Shiller PE Ratio of Medpace Holdings was 107.52. The lowest was 55.86. And the median was 75.49.


Medpace Holdings  (FRA:01P) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Medpace Holdings's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=530.40/6.48
=81.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Medpace Holdings was 107.52. The lowest was 55.86. And the median was 75.49.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Medpace Holdings E10 Related Terms


Medpace Holdings E10 Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings E10 Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 4.57 5.48

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 5.03 5.48 5.96 6.48

FRA:01P vs ICLR, RVTY, CRL: E10 Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Shiller PE Ratio falls into.


FRA:01P
95GF Score
Medpace Holdings Inc FRA:01P
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medpace Holdings's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.689/333.9520*333.9520
=3.689

Current CPI (Jun. 2026) = 333.9520.

Medpace Holdings Quarterly Data

per share eps CPI Adj_EPS
201609 0.116 241.428 0.160
201612 0.000 241.432 0.000
201703 0.187 243.801 0.256
201706 0.205 244.955 0.279
201709 0.210 246.819 0.284
201712 0.253 246.524 0.343
201803 0.324 249.554 0.434
201806 0.385 251.989 0.510
201809 0.446 252.439 0.590
201812 0.536 251.233 0.712
201903 0.451 254.202 0.592
201906 0.646 256.143 0.842
201909 0.572 256.759 0.744
201912 0.702 256.974 0.912
202003 0.688 258.115 0.890
202006 0.568 257.797 0.736
202009 0.925 260.280 1.187
202012 1.110 260.474 1.423
202103 0.958 264.877 1.208
202106 0.880 271.696 1.082
202109 1.097 274.310 1.336
202112 1.168 278.802 1.399
202203 1.535 287.504 1.783
202206 1.381 296.311 1.556
202209 2.071 296.808 2.330
202212 2.001 296.797 2.251
202303 2.120 301.836 2.346
202306 1.781 305.109 1.949
202309 2.080 307.789 2.257
202312 2.256 306.746 2.456
202403 2.944 312.332 3.148
202406 2.555 314.175 2.716
202409 2.712 315.301 2.872
202412 3.505 315.605 3.709
202503 3.395 319.799 3.545
202506 2.688 322.561 2.783
202509 3.289 324.800 3.382
202512 3.988 324.054 4.110
202603 3.702 330.213 3.744
202606 3.689 333.952 3.689

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €6.48 mean?
Medpace Holdings (FRA:01P) has a E10 of €6.48 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' E10 too high?
Medpace Holdings' current E10 is €6.48. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' E10 compare to ICLR and RVTY?
Medpace Holdings' E10 of €6.48 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Diagnostics & Research company?
A good E10 depends on the Medical Diagnostics & Research industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current E10 is €6.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current E10 is €6.48. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current E10 is €6.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (FRA:01P) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14. GuruFocus considers Medpace Holdings to be Modestly Overvalued.

Key valuation signals for FRA:01P:

  • E10: €6.48
  • GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medpace Holdings Business Description

Other Exchanges MEDP:USAMEDP:Mexico
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score

Get the complete analysis for FRA:01P

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€530.40
Price
€463.14
GF Value